Ionis Executive Disposes $515K in Shares After Recent RSU Vesting
Eugene Schneider, executive vice president and chief clinical development officer at Ionis Pharmaceuticals (IONS), sold 6,179 shares on January 30, 2026, for $515,629, after receiving 11,991 performance-based restricted stock units that vested a day earlier. The sale occurred at prices close to the stock’s 52-week high, while the company has seen s…